Long-Term Regression after Discontinuation of Regorafenib Administered for Sorafenib-Refractory Hepatocellular Carcinoma

Detalles Bibliográficos
Autores principales: Bae, Heewon, Gil, Je Ryung, Lee, Moon Hyung, Lim, Taekyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2023
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10267512/
https://www.ncbi.nlm.nih.gov/pubmed/37325494
http://dx.doi.org/10.1159/000529139
_version_ 1785058944456065024
author Bae, Heewon
Gil, Je Ryung
Lee, Moon Hyung
Lim, Taekyu
author_facet Bae, Heewon
Gil, Je Ryung
Lee, Moon Hyung
Lim, Taekyu
author_sort Bae, Heewon
collection PubMed
description
format Online
Article
Text
id pubmed-10267512
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-102675122023-06-15 Long-Term Regression after Discontinuation of Regorafenib Administered for Sorafenib-Refractory Hepatocellular Carcinoma Bae, Heewon Gil, Je Ryung Lee, Moon Hyung Lim, Taekyu Liver Cancer Letter to the Editor S. Karger AG 2023-01-16 /pmc/articles/PMC10267512/ /pubmed/37325494 http://dx.doi.org/10.1159/000529139 Text en Copyright © 2023 by The Author(s). Published by S. Karger AG, Basel https://creativecommons.org/licenses/by-nc/4.0/This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission.
spellingShingle Letter to the Editor
Bae, Heewon
Gil, Je Ryung
Lee, Moon Hyung
Lim, Taekyu
Long-Term Regression after Discontinuation of Regorafenib Administered for Sorafenib-Refractory Hepatocellular Carcinoma
title Long-Term Regression after Discontinuation of Regorafenib Administered for Sorafenib-Refractory Hepatocellular Carcinoma
title_full Long-Term Regression after Discontinuation of Regorafenib Administered for Sorafenib-Refractory Hepatocellular Carcinoma
title_fullStr Long-Term Regression after Discontinuation of Regorafenib Administered for Sorafenib-Refractory Hepatocellular Carcinoma
title_full_unstemmed Long-Term Regression after Discontinuation of Regorafenib Administered for Sorafenib-Refractory Hepatocellular Carcinoma
title_short Long-Term Regression after Discontinuation of Regorafenib Administered for Sorafenib-Refractory Hepatocellular Carcinoma
title_sort long-term regression after discontinuation of regorafenib administered for sorafenib-refractory hepatocellular carcinoma
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10267512/
https://www.ncbi.nlm.nih.gov/pubmed/37325494
http://dx.doi.org/10.1159/000529139
work_keys_str_mv AT baeheewon longtermregressionafterdiscontinuationofregorafenibadministeredforsorafenibrefractoryhepatocellularcarcinoma
AT giljeryung longtermregressionafterdiscontinuationofregorafenibadministeredforsorafenibrefractoryhepatocellularcarcinoma
AT leemoonhyung longtermregressionafterdiscontinuationofregorafenibadministeredforsorafenibrefractoryhepatocellularcarcinoma
AT limtaekyu longtermregressionafterdiscontinuationofregorafenibadministeredforsorafenibrefractoryhepatocellularcarcinoma

Ejemplares similares